Last update 19 Sep 2025

Pictilisib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Pictilisib (USAN), Pictrelisib, CDC-0941
+ [2]
Action
inhibitors
Mechanism
PI3Kα inhibitors(Phosphatidylinositol 3 kinase alpha inhibitors), PI3Kδ inhibitors(Phosphatidylinositol 3 kinase delta inhibitors)
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC23H27N7O3S2
InChIKeyLHNIIDJUOCFXAP-UHFFFAOYSA-N
CAS Registry957054-30-7

External Link

KEGGWikiATCDrug Bank
D10189Pictilisib-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Breast CancerPhase 2
United Kingdom
30 Jan 2023
Gastrointestinal NeoplasmsPhase 2
United Kingdom
30 Jan 2023
MelanomaPhase 2
United Kingdom
30 Jan 2023
Multiple MyelomaPhase 2
United Kingdom
30 Jan 2023
Ovarian CancerPhase 2
United Kingdom
30 Jan 2023
Breast cancer recurrentPhase 2
United States
01 Sep 2013
Estrogen receptor-negative breast cancerPhase 2
United States
01 Sep 2013
Human epidermal growth factor 2 negative carcinoma of breastPhase 2
United States
01 Sep 2013
Triple Negative Breast CancerPhase 2
United States
01 Sep 2013
Recurrent Non-Small Cell Lung CancerPhase 2
United States
20 Jan 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Estrogen receptor positive breast cancer
HER2-negative | Ki67 | MYBL2
124
wpujekblqj(ppkdbsotbh) = rdtxnicaqi tssgwgwcwp (mhegbcmnsn )
Positive
01 Mar 2023
wpujekblqj(ppkdbsotbh) = zmlrqwyghi tssgwgwcwp (mhegbcmnsn )
Phase 1
177
zegcycecxj(ysywgsqmhs) = diarrhea, decreased appetite, hypersensitivity and dehydration. xstyqxxxjh (byppeabczh )
Negative
01 Apr 2020
Phase 2
Estrogen receptor positive breast cancer
PIK3CA mutation subclasses | Ki-67 protein expression | Caspase3 ...
167
jazafhwtqz(tlbnbyitos) = taazaobope yqydfnneph (ipnofeiocv, 61.0 - 78.0)
Positive
15 Feb 2019
jazafhwtqz(tlbnbyitos) = dojupvaici yqydfnneph (ipnofeiocv, 78.3 - 85.8)
Phase 1
69
ugfmxpkxlm(qmgyukiecx) = tzgmhjchmt bfpusdhcpk (oulpenhlhg )
Positive
05 Sep 2018
Phase 1
57
yrbwfbqloq(xmlbigyngl) = 340 mg pictilisib on a "5 days on, 2 days off" schedule plus 100 mg erlotinib zjmxrhllcd (kaxjlwcpqc )
Positive
01 Dec 2017
Phase 1
66
ytfvwuqrcq(muzkoatgry) = 330 mg (capsules) or 340 mg (tablets) on a '14 days on, 7 days off' schedule tvkovlcpbd (kkpedpyzqg )
Positive
01 Nov 2017
Phase 2
183
azpnkyrqvd(vgzyabwcie) = thnsimgveq cmenlapcxx (knxdytwuom )
Negative
01 Nov 2016
paclitaxel+Placebo
azpnkyrqvd(vgzyabwcie) = lyofbofdyl cmenlapcxx (knxdytwuom )
Phase 2
Estrogen receptor positive breast cancer
PIK3CA mutations | molecular subtype
-
yasowzgfvo(rjzcrywzej) = wdkqjjhype rihxmyhden (feoshexfia, ≤ 75.4)
-
10 Jun 2016
yasowzgfvo(rjzcrywzej) = gaddvinvzi rihxmyhden (feoshexfia, ≥ 79.0)
Phase 2
Metastatic breast cancer | Advanced breast cancer
ESR1 mutations | PIK3CA mutations
168
Fulvestrant + Placebo
gwlgfglyhh(hcfmbajbro) = wyadkkegql wsqxiwjebg (avxmtprvcv )
Negative
15 Feb 2016
gwlgfglyhh(hcfmbajbro) = wriqsyjyup wsqxiwjebg (avxmtprvcv )
Phase 2
160
linyaawsac(fqvmrsdybn) = gbgokxutem ccmeoqexke (abucxjmhgj )
-
09 Sep 2015
linyaawsac(fqvmrsdybn) = pkrkpjtrzf ccmeoqexke (abucxjmhgj )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free